PHAXIAM Therapeutics launches a rights issue of approximately €10m, which may be increased up to approximately €11.5m if the extension clause is exercised in full, in order to accelerate the implementation of its clinical strategy
Journalist, investor, healthcare professional, partner or candidate... if you have any questions about PHAXIAM, please do not hesitate to contact our teams.
